Targeting Protein Kinases for Cancer Therapy
- Language: English
- 702 Pages
- Published: March 2010
- Region: World
- Your are here:
- Home
- Categories
- Pharmaceuticals and Healthcare
- Pharmaceuticals
Competitor Analysis: Novel Mitotic Kinase Inhibitors
Competitor Analysis: Novel Mitotic Kinase Inhibitors
- Published: September 2011
- Region: World
- 62 Pages
- La Merie Publishing
The present Competitive Intelligence Report about Novel Mitotic Kinase Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase (CDK) or aurora kinase for treatment of cancer as of September 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Mitosis, a central event in tumor growth, is highly regulated to ensure accurate and equal segregation of genetic materials from parent cells to daughter cells. Main effectors of this process are mitotic spindles and centrosomes.157 Disruption of the process results in aneuploidy, and genomic instability renders the cellular condition optimal for apoptosis to occur. The rationale of targeting mitosis in cancer therapy is substantiated by the successful clinical development of tubulin-disrupting agents, such as vinca alkaloids and taxanes.
The coordination of progression through mitosis is mainly orchestrated by
READ MORE >
1. Novel Mitotic Kinase Inhibitors Cycline-dependent kinase (CDK1) inhibitors
Polo-Like Kinase 1 (Plk-1) Inhibitors
Plk-1 Inhibitors
Plk-2 Inhibitors Aurora Kinase Inhibitors
Selective Aurora A Kinase Inhibitors
Selective Aurora B Kinase Inhibitors
Dual Aurora B and C Kinase Inhibitors
Pan-Aurora Kinase Inhibitors
Dual- and Multi-Target Aurora Kinase Inhibitors
2. Corporate Novel Mitotic Kinase Inhibitors R&D Pipelines
ACT Biotech
Agennix
Amgen
Astex Therapeutics
AstraZeneca
Bayer HealthCare Pharmaceuticals
Boehringer Ingelheim
China Medical University
Chroma Therapeutics
Critical Outcome Technologies
Cyclacel Pharmaceuticals
Eli Lilly
EntreMed
Exelixis
GlaxoSmithKline (GSK)
Imperial College London
Johns Hopkins Medical Institution
Lead Discovery Center
Leukemia & Lymphoma Society (LLS)
Ligand Pharmaceuticals
ManRos Therapeutics
Marina Biotech
Merck & Co.
Merck Serono
Mount Sinai School of Medicine
Nerviano Medical Sciences
Novartis
Oncanova Therapeutics
Pfizer
Piramal Life Sciences
ProBioDrug
Rigel
S*Bio
Sanofi
Sareum
Selected Value Therapeutics
Sunesis Pharmaceuticals
Takeda Pharmaceutical Co.
Tekmira
The Institute of Cancer Research
Tragara Pharmaceuticals
TransTech Pharma
University of South Carolina
Telik
| Format | Properties | |
|---|---|---|
| Electronic (PDF) | The report will be emailed to you. The report is sent in PDF format. | This is a single user license, allowing one specific user access to the product. |
| Site License | The report will be emailed to you. The report is sent in PDF format. | This is a site license, allowing all users within a given geographical location of your organisation access to the product. |
| Enterprisewide | The report will be emailed to you. The report is sent in PDF format. | This is an enterprise license, allowing all employees within your organisation access to the product. |
Note: Product cover images may vary from those shown
RELATED PRODUCTS
-
-
Polypharmacology in Drug Discovery
- Language: English
- 536 Pages
- Published: March 2012
- Region: World
-
Kinase Inhibitor Drugs. Wiley Series in Drug Discovery and Development
- Language: English
- 510 Pages
- Published: November 2009
-
Protein Kinases as Drug Targets. Methods and Principles in Medicinal Chemistry
- Language: English
- 396 Pages
- Published: February 2011
-
Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking
- Language: English
- 24 Pages
- Published: May 2009
- Region: World
-
Molecularly Driven Management and Maintenance Treatment of NSCLC: Physician and Payer Perspectives on the Changing Treatment Paradigms in Europe
Molecularly Driven Management and Maintenance Treatment of NSCLC: Physician and Payer Perspectives on the Changing Treatment Paradigms in Europe
- Language: English
- 170 Pages
- Published: October 2011
- Region: World
-
Competitor Analysis: Raf Inhibitors
- Language: English
- 21 Pages
- Published: May 2009
- Region: World
FROM -
Competitor Analysis: Plk-1 Inhibitors
- Language: English
- 12 Pages
- Published: May 2009
- Region: World
FROM -
Competitor Analysis: CHK and KSP/Eg5 Inhibitors
- Language: English
- 19 Pages
- Published: August 2009
- Region: World
FROM -
CDK Inhibitors Patent Landscape - 2009/10
- Language: English
- 83 Pages
- Published: October 2009
- Region: World
FROM
